"According to the Centers for Disease Control and Prevention, nearly 13 million individuals seriously consider suicide annually, and around 1.5 million attempt suicide. Preliminary data for 2024 indicate a potential increase in the age-adjusted suicide rate, estimated at 14.7 per 100,000 people. In the nearly two years since the launch of the 988 Suicide and Crisis Lifeline in 2022, the phone line has received more than 10 million contacts. Monthly call volume has surpassed 600,000 calls per month since early 2025."
"Clinical trials have shown that ketamine is highly effective for rapidly reducing suicidal thoughts. In the past, fast-track designation has been granted based on robust data from well-controlled trials. In the case of ketamine, a Columbia University study reported that 55% of patients with suicidal ideation responded to intravenous ketamine. In French government-sponsored research, 63% of patients achieved complete remission of suicidal ideation within three days of receiving IV ketamine."
In 2023 there were 49,316 suicides in the U.S., about one death every 11 minutes. Nearly 13 million people seriously consider suicide annually and about 1.5 million attempt suicide. Preliminary 2024 data show a possible rise in the age-adjusted suicide rate to 14.7 per 100,000. The 988 Suicide and Crisis Lifeline has received over 10 million contacts and exceeded 600,000 monthly calls since early 2025. On August 11, 2025, the FDA granted fast-track designation to NRX-100, a preservative-free IV ketamine formulation for suicidal ideation in depression, including bipolar depression. Clinical trials report rapid reductions in suicidal thinking, with reported response and remission rates of roughly 55% and 63%. NRx Pharmaceuticals plans to seek accelerated approval by December 2025, which could make NRX-100 the first FDA-approved IV ketamine for suicidal ideation in depression.
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]